Prima BioMed Receives ~A$860,000 Tax Credit Payment From French Government
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 02/12/17 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company"), is pleased to announce that its French subsidiary, Immutep S.A.S., has received EUR 618,307 (approximately A$860,000) in payment of a research tax credit from the French state under the Crédit d'Impôt Recherche scheme. The cash payment was with respect to expenditure incurred by Immutep on European R&D activities in the 2015 calendar year, related to the Company's LAG-3 programs.
The "Crédit d'Impôt Recherche" (CIR), meaning "Research Tax Credit," is a French government tax incentive first introduced in 1983 by which French companies doing research and development in Europe, can be reimbursed 30% of the eligible expenditure.
Immutep has a laboratory at Châtenay-Malabry in south-western Paris. It is currently working on new products in addition to the development work related to the existing Prima BioMed pipeline, which includes the lead compound IMP321. Recently, the company announced it has developed a new early stage product candidate, a humanised IgG4 monoclonal, agonist antibody to be known as IMP761.
Prima BioMed is a globally active biotechnology company and a leader in the development of immunotherapeutic products. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Matthew Beck
The Trout Group LLC
+1 (646) 378-2933
Mr Matthew Gregorowski
Citadel-MAGNUS
+61 (0) 422 534 755
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.02.2017 - 01:50 Uhr
Sprache: Deutsch
News-ID 523539
Anzahl Zeichen: 0
contact information:
Town:
SYDNEY, AUSTRALIA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 317 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prima BioMed Receives ~A$860,000 Tax Credit Payment From French Government"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
